Imovax Polio

Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Poliovirus (Inactivated) Type 1 (Mahoney Strain), the active ingredient in Imovax Polio, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It prevents poliomyelitis caused by poliovirus types 1, 2, and 3.

GNH USA supplies Imovax Polio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imovax Polio is an inactivated poliovirus vaccine used to prevent poliomyelitis, a viral infection of the nervous system.

- Poliomyelitis (type 1): Induces immunity to prevent infection with type 1 poliovirus. - Poliomyelitis (type 2): Induces immunity to prevent infection with type 2 poliovirus. - Poliomyelitis (type 3): Induces immunity to prevent infection with type 3 poliovirus.

Common side effects are usually mild and transient, reflecting the local immune response to the injected antigen.

Common Side Effects: - Pain at the injection site: mild to moderate discomfort. - Redness or swelling: localized erythema around the injection area. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: mild tension‑type headache. - Fatigue: temporary tiredness after vaccination. - Irritability (in children): brief fussiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare autoimmune neuropathy. - Seizures: infrequent neurologic event. - Severe hypotension: sudden drop in blood pressure. - Myocarditis: inflammation of heart muscle. - Persistent high fever: >39 °C lasting more than 48 hours.

Before administering Imovax Polio, healthcare professionals should consider several safety measures.

- Screen for contraindications: known hypersensitivity to any vaccine component. - Assess immune status: immunocompromised individuals may have reduced response. - Pregnancy: safety not established; weigh benefits versus potential risks. - Concurrent vaccines: may be given according to recommended immunisation schedule. - Observe after injection: monitor for immediate allergic reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other agents that influence immune response or vaccine efficacy.

Major Interactions (Avoid): - Live viral vaccines: concurrent administration may reduce immune response to either product. - Immunoglobulin therapy: may neutralise vaccine antigens and diminish effectiveness. - Blood products: can interfere with antibody formation.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may mask post‑vaccination fever. - Corticosteroids: may blunt antibody response when used at high doses.